EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High Occurrence of a Missense Variant (c.471C>A) in the FGF23 Gene Related to Hyperostosis–Hyperphosphatemia Syndrome With a Possible Founder Effect

Maryam Sedghi, Elika Esmaeilzadeh Gharehdaghi, Vahid Ziaee iD, Farzaneh Abbasi, Hamid Reza Aghaei Meybodi, Elina Smiley, Mehrzad Mehdizadeh, Seyyed Reza Raeeskarami, Nahid Aslani, Sahar Naderi Shiran, Mehdi Vafadar, Mahsa M Amoli iD

Human Mutation · 2025

DOI: 10.1155/humu/6382674 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Mutation, 2025. Verfasst von Maryam Sedghi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Disorders Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Science, Tehran…. Hauptthemen laut MEDLINE: Mutation, Missense, Fibroblast Growth Factors, Hyperphosphatemia, Hyperostosis. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The autosomal recessive metabolic disorder hyperostosis–hyperphosphatemia syndrome (HHS) is characterized by hyperphosphatemia, hyperostosis, and recurrent bone lesions. Patients may develop ectopic and vascular calcification and may present diaphyseal pain of the long bones that is misdiagnosed as osteomyelitis. Mutations in GALNT3 and FGF23 genes were detected in patients with HHS. The main manifestations of these patients are increased levels of phosphate reabsorption from kidneys and painful swelling of long bones alongside with normal levels of vitamin D and parathormone.

Method

We performed whole‐exome sequencing (WES) in seven Iranian patients. These patients were referred from several specialist clinics. Seven irrelevant families were examined for genetic mutations.

Results

WES revealed the deleterious missense mutation c.471C>A, p. F157L in all affected members of six families. The variant c.1524+1G>A in the GALNT3 gene was found in the remaining patient which is reported previously. These variants were confirmed utilizing segregation studies in the pedigrees.

Conclusion

Our data together with previous studies related to mutations in FGF23 in Iran strongly support that p. F157L mutation is abundantly prevalent in patients with Iranian origin and is likely to be a founder mutation; however, it requires further confirmative study. The result of this study suggests that p. F157L mutation should be investigated at the first step in genetic analysis of patients with HHS. This enables fast and accurate focused molecular diagnosis and would be effective for use in carrier screening as well as in prenatal diagnosis (PND) and preimplantation genetic diagnosis (PGD).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mutation, MissenseFibroblast Growth FactorsHyperphosphatemiaHyperostosisFounder EffectHumansFibroblast Growth Factor-23MaleFemalePedigreeN-AcetylgalactosaminyltransferasesPolypeptide N-acetylgalactosaminyltransferaseIranExome SequencingChildAdultAdolescent

Stichwörter der Autor:innen

FGF23HSS syndromemutation c.471C>A

Substanzen

Fibroblast Growth Factor-23FGF23 protein, humanFibroblast Growth FactorsN-AcetylgalactosaminyltransferasesPolypeptide N-acetylgalactosaminyltransferase

Autor:innen und Institutionen

  • Metabolic Disorders Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Science, Tehran, Iran.
  • Department of Pediatrics, Tehran University of Medical Sciences, Tehran, Iran.
  • Pediatric Rheumatology Research Group, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Growth and Development Research Center, Children's Medical Center Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Evidence Based Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • CLS Department, School of Health Profession, The University of Texas Medical Branch, Galveston, Texas, USA.

ORCID-Profile: Vahid Ziaee, Mahsa M Amoli

Förderung

  • Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences

Zitieren

APA

Sedghi, M., Gharehdaghi, E. E., Ziaee, V., Abbasi, F., Meybodi, H. R. A., Smiley, E., Mehdizadeh, M., Raeeskarami, S. R., Aslani, N., Shiran, S. N., Vafadar, M., & Amoli, M. M. (2025). High Occurrence of a Missense Variant (c.471C>A) in the FGF23 Gene Related to Hyperostosis–Hyperphosphatemia Syndrome With a Possible Founder Effect. Human Mutation. https://doi.org/10.1155/humu/6382674

Vancouver

Sedghi M, Gharehdaghi EE, Ziaee V, Abbasi F, Meybodi HRA, Smiley E, et al. High Occurrence of a Missense Variant (c.471C>A) in the FGF23 Gene Related to Hyperostosis–Hyperphosphatemia Syndrome With a Possible Founder Effect. Human Mutation. 2025. doi:10.1155/humu/6382674

BibTeX
@article{Sedghi2025,
  author = {Sedghi, Maryam and Gharehdaghi, Elika Esmaeilzadeh and Ziaee, Vahid and Abbasi, Farzaneh and Meybodi, Hamid Reza Aghaei and Smiley, Elina and Mehdizadeh, Mehrzad and Raeeskarami, Seyyed Reza and Aslani, Nahid and Shiran, Sahar Naderi and Vafadar, Mehdi and Amoli, Mahsa M},
  title = {High Occurrence of a Missense Variant (c.471C>A) in the FGF23 Gene Related to Hyperostosis–Hyperphosphatemia Syndrome With a Possible Founder Effect},
  journal = {Human Mutation},
  year = {2025},
  doi = {10.1155/humu/6382674}
}
Kostenlos starten →